Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: page 6

page 6

posted on Aug 25, 2008 01:32PM

PTSC has been subject to stock price jitters on:

Heavy retail (near 90%), limited institutional investor base

Lack of visibility to new licensees, inability to forecast future revenues

USPTO patent re-examinations, Patent Reform Act legislation

Becoming an operating company can mitigate these concerns







I dont understand the inability to forecast future revenues....... i assume TPL and PTSC have a goal amount of accounts to visit/sign per quarter... revenue per quarter..etc.... In sales you always have a budget or goal to reach...otherwise there is no incentative... there is no measuring stick... how are sales or management held accountable...

Share
New Message
Please login to post a reply